Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
16,517 results
- Ivermectin and Human Immunity: Complete Statistical AnalysisIndependent statistical analysis of Ivermectin and Human Immunity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03459794).
- IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing: Complete Statistical AnalysisIndependent statistical analysis of IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02026193).
- IVIDAIndependent statistical analysis of Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3: Complete Statistical AnalysisIndependent statistical analysis of IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03401073).
- IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02697292).
- IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff: Complete Statistical AnalysisIndependent statistical analysis of IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ivWatch Model 400: Device Validation for Non-Infiltrated Tissues: Complete Statistical AnalysisIndependent statistical analysis of ivWatch Model 400: Device Validation for Non-Infiltrated Tissues: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02120443).
- ivWatch Sensor: Device Validation for Infiltrated Tissues: Complete Statistical AnalysisIndependent statistical analysis of ivWatch Sensor: Device Validation for Infiltrated Tissues: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04064229).
- IVYIndependent statistical analysis of A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IWPIndependent statistical analysis of Immigrant Well-being Project: Transdisciplinary Ecological Mental Health Intervention for Mexican Immigrants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IWWPIndependent statistical analysis of It's WeWomen Plus Intervention for Health, Safety and Empowerment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04098276).
- IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE): Complete Statistical AnalysisIndependent statistical analysis of IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ixabepilone in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00087139).
- Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00095979).
- Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ixabepilone to Treat Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone to Treat Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00924066).
- Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- IXORA-RIndependent statistical analysis of A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- IXTENDIndependent statistical analysis of Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation: Complete Statistical AnalysisIndependent statistical analysis of J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- JACOBIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer: primary endpoint…
- JADE TEENIndependent statistical analysis of JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- JakStat2Independent statistical analysis of Topical Interferon Gamma for Macular Edema Secondary to Uveitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01376362).
- Janus Kinase Inhibition in Granuloma Annulare: Complete Statistical AnalysisIndependent statistical analysis of Janus Kinase Inhibition in Granuloma Annulare: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05650736).
- Japanese AMLIndependent statistical analysis of Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Japanese IP-TN Trial: Complete Statistical AnalysisIndependent statistical analysis of Japanese IP-TN Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02831569).
- Japanese Phase 1 Trial of Sym004 in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Japanese Phase 1 Trial of Sym004 in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01955473).
- Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients: Complete Statistical AnalysisIndependent statistical analysis of Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD): Complete Statistical AnalysisIndependent statistical analysis of JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- JAWLINEIndependent statistical analysis of Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study: Complete Statistical AnalysisIndependent statistical analysis of JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02732691).
- JET-ISRIndependent statistical analysis of JetStream Atherectomy for the Treatment of In-stent Restenosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02730234).
- JETiIndependent statistical analysis of JETi Lower Extremity Arterial Thrombosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04370691).
- Jewel Electrophysiology (EP) Lab Study: Complete Statistical AnalysisIndependent statistical analysis of Jewel Electrophysiology (EP) Lab Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05490459).
- JintronixIndependent statistical analysis of A New Adaptive Physical Activity Technology in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02467491).
- JiVitA-3Independent statistical analysis of Antenatal Micronutrient Supplementation and Infant Survival: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00860470).
- JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- JOTIndependent statistical analysis of Journey of Transformation Curriculum for Native American Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05274217).
- JOTROL PK, Safety, and Food Effect Assessment: Complete Statistical AnalysisIndependent statistical analysis of JOTROL PK, Safety, and Food Effect Assessment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04668274).
- Journeys to Wellness: A Transplant Candidate Study: Complete Statistical AnalysisIndependent statistical analysis of Journeys to Wellness: A Transplant Candidate Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01254214).